NewLink Genetics Corporation (NLNK - Free Report) was a big mover last session, as the company saw its shares rise nearly 30% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company—as the stock is now up 156.1% in the past one-month time frame.
The stock gained after the company reported that its advanced melanoma’s drug, IDO-inhibitor indoximod, received positive results from the phase 2 clinical study.
The company has seen two negative estimate revisions in the past few months, while its Zacks Consensus Estimate for the current quarter has also moved lower over the past few months, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward, to see if this recent move higher can last.
NewLink Genetics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is positive.
A better-ranked stock in the Medical - Biomedical and Genetics industry is Akari Therapeutics PLC (AKTX - Free Report) , which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is NLNK going up? Or down? Predict to see what others think: Up or Down
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>